I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
5.01
+0.77 (18.16%)
Aug 14, 2025, 11:42 AM - Market open
I-Mab Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
576.12M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMAB News
- 13 days ago - Everest Medicines Expands Strategic Investment in I-MAB - PRNewsWire
- 13 days ago - I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares - GlobeNewsWire
- 4 weeks ago - I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health - GlobeNewsWire
- 6 weeks ago - I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 6 weeks ago - I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research - GlobeNewsWire
- 7 weeks ago - I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 - GlobeNewsWire
- 3 months ago - I-Mab to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire